GSK plc (GSK) Stock Analysis
Oversold Bounce setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $51.83, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial... Read more
Hold if already holding. Not a fresh buy at $51.83, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5. Chart setup: Oversold RSI 21, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 4/6 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $51.83, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5. Chart setup: Oversold RSI 21, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Target $58.38 (+12.6%), stop $48.82 (−6.2%), A.R:R -0.5:1. Score 6.3/10, moderate confidence.
Take-profit target: $58.38 (+13.6% upside). Target $58.38 (+12.6%), stop $48.82 (−6.2%), A.R:R -0.5:1. Stop-loss: $48.82.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5.
GSK plc trades at a P/E of 13.4 (forward 9.9). TrendMatrix value score: 6.9/10. Verdict: Hold.
32 analysts cover GSK with a consensus score of 3.4/5. Average price target: $58.
What does GSK plc do?GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty...
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.